newsfilter
← Latest News
GlobeNewswire·

MyoKardia Announces 48-week Data from PIONEER-OLE Study of Mavacamten

Mavacamten’s Safety and Efficacy Profile in the PIONEER Study Maintained Through One Year in Open-Label Extension Study of 12 Patients with Symptomatic, Obstructive HCM Evidence Suggests Mavacamten’s...